Disrupting Pathogen Virulence

Bactolife™ develops novel biological solutions against gastrointestinal infections in humans and animals

Antimicrobial resistance development is a major and increasing threat to human health worldwide. It is expected that deaths attributed to infectious diseases will surpass the number of cancer related deaths by 2050.

Bacterial gastrointestinal infections

Antibiotics, the only current treatment

0
DETECTED CASES OF CHOLERA PER YEAR
0
DEATHS/YEAR DUE TO GI INFECTIONS
0
DEATHS/YEAR BY 2050 DUE TO ANTIMICROBIAL RESISTANCE
USD
0
trillion
GLOBAL BURDEN BY 2050 DUE TO ANTIMICROBIAL RESISTANCE

“World faces decade at risk from antibiotic-resistant bugs.”

Bill Gates, philanthropist.

“If the world fails to mount a more serious effort to fight infectious diseases, antimicrobial resistance will increasingly threaten to send the world back to a pre-antibiotic age.”

Gro Harlem Brundtland, former Prime Minister of Norway and Director of the World Health Organization (1998 to 2003).

Innovation is needed to change the treatment paradigm surrounding infectious diseases

Bactolife™ enables collaboration between host and microbiome
In Bactolife™, we understand that we need to revise the way we treat and handle infections. Therefore, we work towards the equilibrium rather than eradicating some components of the holobiont, a term that describes how the host and all its symbiotic microbes interact with each other as a whole. As infants are protected from pathogens by maternal antibodies present in breastmilk, Bactolife™’s VIPs™ emulate such protection by binding to virulence factors (i.e. toxins and adhesins), thereby reducing virulence of pathogens.

Contact us

bactolife-full-logo